Inventor · disambiguated record
John Paolini
Also filed as: PAOLINI JOHN · PAOLINI JOHN F
6 granted patents·11 pending applications·2 citations·filing 2008–2025
74Inventor score
Top patents by PatentIndex Score
17 records- 0184US12201673B2Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion proteinREGENERON PHARMA·Filed 2024·Granted Jan 21, 2025·0 cites·21 claims
- 0284US2025345396A1Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion proteinREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 0383US11325979B2Treatment of cytokine release syndrome with GM-CSF antagonistsKINIKSA PHARMACEUTICALS LTD·Filed 2021·Granted May 10, 2022·2 cites·28 claims
- 0482US11844765B2Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion proteinREGENERON PHARMA·Filed 2023·Granted Dec 19, 2023·0 cites·30 claims
- 0579US11944666B2Treatment of inflammatory conditions delivery of interleukin-1 receptor antagonist fusion proteinREGENERON PHARMA·Filed 2022·Granted Apr 2, 2024·0 cites·17 claims
- 0678US2025236676A1TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODYKINIKSA PHARMACEUTICALS LTD·Filed 2024·Application pending·0 cites
- 0776US11464830B2Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion proteinREGENERON PHARMA·Filed 2021·Granted Oct 11, 2022·0 cites·16 claims
- 0874US2024101690A1TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODYKINIKSA PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 0971US11026997B2Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion proteinREGENERON PHARMA·Filed 2018·Granted Jun 8, 2021·0 cites·33 claims
- 1071US2024117058A1Treatment of cytokine release syndrome with gm-csf antagonistsKINIKSA PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 1171US2021283224A1Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion proteinREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1265US2021054085A1Treatment of skin diseases or disorders by delivery of anti-osmrb antibodyKINIKSA PHARMACEUTICALS LTD·Filed 2019·Application pending·0 cites
- 1359US2023287132A1Methods of treating or reducing risk of transplant rejectionKINIKSA PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 1458US2021284744A1Treatment of cytokine release syndrome with gm-csf antagonistsKINIKSA PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 1556US2023183367A1Pharmaceutical compositions of humanized anti-cd40 antibodies and uses thereofKINIKSA PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 1651US2022010007A1Treatment for Giant Cell ArteritisKINIKSA PHARMAEUTICALS LTD·Filed 2019·Application pending·0 cites
- 1741US2010260841A1Method of Treating Atherosclerosis, Dyslipidemias and Related ConditionsPAOLINI JOHN F·Filed 2008·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John Paolini files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →